| abstract |
The present invention relates to compounds of the general formula I wherein R1 is lower alkyl, aryl or heteroaryl, wherein aryl and heteroaryl are optionally substituted by halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cyano, amino, di-lower alkyl amino or morpholinyl; R2 is lower alkyl, -(CH2)n-aryl, -(CH2)n-heteroaryl or -(CH2)n-cycloalkyl, wherein the aryl or heteroaryl groups are optionally substituted by one or more substituents, selected from the group consisting of halogen, lower alkyl, cyano, or lower alkoxy; R3 is hydrogen or lower alkyl; R4 is aryl or heteroaryl, wherein at least one ring is aromatic in nature, wherein aryl and heteroaryl are optionally substituted by one or more substituents, selected from the group consisting of halogen, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl; X is a bond or -OCH2-; n is 0, 1 or 2; or to pharmaceutically acceptable acid addition salts thereof, with the exception of 4-methoxy-N-[2-oxo-2-(phenylamino)ethyl]-N-phenyl-benzamide, 4-chloro-N-[2-[(4-methylphenyl)amino]-2-oxoethyl]-N-phenyl-benzamide, 4-chloro-N-[2-[5-chloro-2-methoxyphenyl)amino]-2-oxoethyl]-N-benzamide, 4-methyl-N-(2-oxo-2-[(2,4,6-trichlorophenyl)amino]ethyl]-N-benzamide, N-[2-[(4-methylphenyl)amino]-2-oxoethyl]-N-phenyl-benzamide, 4-methyl-N-[2-[(4-methylphenyl)amino]-2-oxoethyl]-N-phenyl-benzamide, 4-chloro-N-(2-oxo-2-[(2,4,6-trichlorophenyl)amino]ethyl]-N-benzamide and N-[2-[(2, 4-dimethoxyphenyl)amino]-2-oxoethyl]-N-[(2-fluorophenyl)methyl]- benzeneacetamide. and to their use in the treatment of neurological and neuropsychiatric disorders. |